BMRN: צמיחה צפויה ברווח למניה לשנה הבאה biomarin.com
A stable liquidity surplus and high margins on orphan drugs create a reliable cash flow, which is confirmed by the projected earnings per share (EPS) for year n+1 for BioMarin Pharmaceutical (BMRN). The 112.10 metric determines this level. Sales growth for Voxzogo and acquisition potential drive development, although management faces pressure from shareholders demanding the minimization of trial risks and an accelerated path to sustainable profitability.
פילוחים אנליטיים ודוחות נתונים של חברת BioMarin Pharmaceutical Inc. (BMRN)
Fundamental asset selection is based on a business's ability to generate excess profit in the future. This indicator measures the expected earnings per share (EPS) trend, reflecting the market consensus regarding net income growth rates. For BioMarin Pharmaceutical (BMRN), this metric confirms the effectiveness of transitioning toward the commercial scaling of orphan drugs rather than risky development projects. The EPS consensus forecast vector on the GURU.Markets platform allows for a real-time assessment of the current portfolio restructuring's success.
